Infectologia
A efetividade da vacina da AstraZeneca em idosos durante a circulação da variante gama do SARS-CoV-2 em São Paulo foi de 77,9% contra Covid-19 sintomática, 87,6% contra internação e 93,6% contra morte.
29 Out, 2021 | 14:59h
Comentário no Twitter (fio – clique para saber mais)
Effectiveness of Oxford-AstraZeneca COVID-19 vaccine by dose in over 60s in São Paulo state, published today in @NatureComms with @juliocroda @otavio_ranzani @datcummings as part of the VEBRA COVID-19 group 1/8https://t.co/zIbPb45nEJ
— Matt Hitchings (@MHitchingsEpi) October 28, 2021
Atualização sobre as sequelas pós-agudas da infecção por SARS-CoV-2: cuidados clínicos aos portadores de “long Covid”.
29 Out, 2021 | 14:57hConteúdos relacionados:
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)
Subnotificação de mortes limita a compreensão sobre o verdadeiro impacto da Covid-19.
29 Out, 2021 | 14:54hUnder-reporting of deaths limits our understanding of true burden of covid-19 – The BMJ
Conteúdos relacionados:
Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.
Just how do deaths due to COVID-19 stack up?
Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.
COVID-19 has caused 6.9 million deaths globally, more than double what official reports show
Comentário no Twitter
Mortality data have been essential in understanding the spread of covid-19 and navigating the trade-offs that underlie political decision making, yet under-reporting in official death records has greatly obscured this understanding.
What should be done?https://t.co/pI8aVpa3NR
— The BMJ (@bmj_latest) October 14, 2021
Vacinas de mRNA induzem memória imunológica durável contra SARS-CoV-2 e variantes de preocupação.
29 Out, 2021 | 14:53hmRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science
Comentário do autor no Twitter (fio – clique para saber mais)
Antibodies come and go, but memory cells are forever (maybe not forever, but at least 6 months). Our latest in @ScienceMagazine: https://t.co/YHHBMrMsTA
How long does immune memory last after #mRNA vax? Is it effective vs. variants? What about “boosted” responses?
Full 🧵⬇️… pic.twitter.com/oZ5BxLuVdw
— Rishi Goel (@rishirajgoel) October 14, 2021
Nove palavras pandêmicas que poucos acertam como utilizar.
29 Out, 2021 | 14:50hNine Pandemic Words That Almost No One Gets Right – The Atlantic
Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.
28 Out, 2021 | 16:22hComentários:
The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM
The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews
Conteúdos relacionados:
Comentário no Twitter
NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY
— The Lancet (@TheLancet) October 27, 2021
Estudo randomizado | Tratamento precoce da Covid-19 com sotrovimabe (anticorpo neutralizante do SARS-CoV-2) está associado a risco reduzido de internação.
28 Out, 2021 | 16:18h
Comentário no Twitter
In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB
— NEJM (@NEJM) October 27, 2021
Merck autoriza que outros países produzam novo antiviral contra COVID-19.
28 Out, 2021 | 16:17hMerck to allow other nations to produce new COVID-19 antiviral – CIDRAP
Ver também:
Merck will allow drugmakers in other countries to make its COVID-19 pill – NPR
Conteúdos relacionados:
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Dois estudos observacionais levantam dúvidas sobre os efeitos do fechamento de escolas na redução da transmissão da Covid-19.
28 Out, 2021 | 16:15hEstudo 2: The impact of school opening model on SARS-CoV-2 community incidence and mortality – Nature Medicine
Comentários no Twitter
Results from a study in the US published in @NatureMedicine indicate that schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2. However, the impacts are variable and more study is needed. https://t.co/NFt1vNNb76 pic.twitter.com/fNgsJn6WLg
— Nature Portfolio (@NaturePortfolio) October 27, 2021
(fio – clique para saber mais)
2 new @NatureMedicine papers
First from half of US public school data
"Schools can open for in-person learning during the pandemic with minimal contribution to sustained community incidence of infections, provided other public safety measures are adopted."https://t.co/gn8MzrYVxE pic.twitter.com/qGfQLMzDEW— Eric Topol (@EricTopol) October 27, 2021
O que as vacinas contra COVID em crianças mais novas podem significar para a pandemia.
28 Out, 2021 | 16:14hWhat COVID vaccines for young kids could mean for the pandemic – Nature
Conteúdo relacionado: FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.